More than 58 million Americans have actinic keratosis, the most common precancer in the country.[1] Their options today are liquid nitrogen in a doctor's office or a month of topical chemotherapy that causes painful, visible red blemishes. Given current options, one patient in four gives up on treatment within a year.
GZ21T is a topical cream in clinical development aimed at that gap, and it is where the largest share of this raise is going. The last 15 minutes are yours. Bring questions.
Add your name and we will send the join link plus a calendar hold. Cannot attend on the day? Register anyway and we will send the replay.
Check your inbox for the join link. It lands within a few minutes. Add the event to your calendar so it does not slip past you.
A dermatologist and an executive walk through the program, then hand the floor to you.
What patients with actinic keratosis are offered today, and why so many stop treatment before it works.
Cameron West, MD on the clinical bar GZ21T needs to clear, and what follows if it does.
Jason West on why dermatology is the fastest readout in the pipeline and what this round funds.
Your question goes to the people running the trial and the company.
Freezing clears the spots a doctor can see. Chemotherapy creams reach more skin but leave a patient's face raw for weeks, so plenty of people quit. GZ21T is in clinical development as a third option, and the trial will show whether it can be one.
Actinic keratosis ranks as the most common precancer in the country, and patients who have one tend to develop more over time. The need keeps coming back.
Management will explain why dermatology is expected to produce data before the company's other programs, and how this round is allocated.
The COO treats this disease and helped publish the preclinical research behind GZ21T. You can ask him directly.
NextGen Scientific in the press
Straight from the dermatologist who treats these patients and the executive who runs the numbers.
Register for the Webinar
